ZNRF3 and prostate carcinoma: Similarly, the strong upregulation of cell cycle progression, E2F/DREAM, and PRC1/2 pathways in tumors harboring ZNRF3 loss further supports a link between this tumor suppressor and pathways with established links to prostate cancer aggression.